ALMS was a well-designed, randomized, controlled trial that included 370 patients with systemic lupus erythematosus (SLE) and class III, IV, or V nephritis. Like every recent major trial of new ...

No writing assistance was utilized in the production of this manuscript. Lupus nephritis (LN) is one of the most serious complications of systemic lupus erythematosus. Immunological features ...

2 Because SLE can cause diverse symptoms ... people develop one of the most dangerous manifestations of SLE: lupus nephritis (LN), characterized by immune system induced inflammation of the ...

Regular assessment of renal function, proteinuria, and serological markers is crucial for monitoring lupus nephritis progression and treatment response. Long-term follow-up data offer valuable ...

Financial constraints and limited healthcare access are significant barriers to timely lupus nephritis treatment, affecting patient outcomes. Patient assistance programs, educational initiatives ...

as an option for adults at the more severe end of the lupus nephritis spectrum, in other words, those with class 3, 4, and 5 disease, according to the guidance. The drug was approved by the ...

in people with active/chronic International Society of Nephrology/Renal Pathology Society 2003 proliferative Class III or IV lupus nephritis, with or without Class V. The study enrolled 271 people, ...

No new safety signals were identified. “Gazyva/Gazyvaro achieved a robust complete renal response rate in lupus nephritis, which is associated with long-term preservation of kidney function and ...

Belimumab added to standard of care (SoC) induction therapy controls disease activity and reduces steroid use in patients with proliferative lupus nephritis ... biopsy-proven class 3 or 4 LN ...

Biomarker for Lupus Nephritis Our Michael Jon Barlin Pediatric Lupus Research Program also is supporting a project led by Kathleen Sullivan, MD, MPH, The Children’s Hospital of Philadelphia. Dr.

The REGENCY study met its primary endpoint, demonstrating statistically significant and clinically meaningful treatment benefits in people with active lupus nephritis – – Gazyva is designed to ...

“We are thrilled to achieve this milestone that will provide access to LUPKYNIS in Japan, where there is a high rate of lupus nephritis among ... trial and AURORA 2 extension trial, demonstrated ...